A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Filgotinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Psoriatic arthritis; Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis; Uveitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.